Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q1 FY24 Earnings Presentation
15 slides from Zydus Lifesciences's earnings presentation, Aug 11, 2023
Slide 1: Exchange filing cover letter: Investor Presentation
zyd Dedicated To Life August 11, 2023 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentat
Slide 2: Zydus Lifesciences Limited Earnings Presentation: Q1 FY24
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q1 FY24 11th August, 2023 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q1 FY24: At a Glance
Q1 FY24: At a Glance zyd~ Dedicated To Life Revenues from Highlights of Q1 FY24 R&D Operations ' '' . ''' ❑ Total revenues grew 30% YoY, led by US and EM& EU formulations '' ' ''' Rs. 51,396 mn '' ' ''' Rs. 3,239 mn businesses. 30% YoY 6.3% of revenues '' '' '' '' '' ~ ------------------------------
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) zyd~ Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 61.9% 60.2% 64.5% 66.2% 67.4% 50,106 51,396 34,652 33,146 39,644 40,053 42,571 27,468 24,551 24,109 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Total R&D (Rs. mn) and
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) zyd~ PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 11,011 8,979 2,828 2,554 2,157 2,040 2,203 6,229 5,212 5,225 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Net Debt/ EBITDA Net Working Capital* (Rs. mn) 63,906 56,290 57,051 51,218
Slide 7: India Formulations business
India Formulations business zyd~ Dedicated To Life Sustained growth momentum driven by focused execution Highlights for the quarter India Formulations Sales (Rs. mn) Q1 FY24 Revenue Contribution ▪ Branded business grew by 10% YoY. Excluding the 12,648 12,316 12,896 12,270 impact of NLEM led price re
Slide 8: Consumer Wellness
Consumer Wellness zyd~ Dedicated To Life Leveraging strong brand equity to navigate through challenging times Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q1 FY24 Revenue Contribution 6,916 7,075 6,936 ▪ Unseasonal rains during the first half of the quarter impacted the offtake of a k
Slide 9: US Formulations business
US Formulations business zyd~ Dedicated To Life Delivering sustained sequential growth through the year Highlights for the quarter US Formulations Sales (Rs. mn) Q1 FY24 Revenue Contribution 24,541 ▪ Registered strong YoY growth driven by new launches 22,525 and improvement in base business. 19,250
Slide 10: Emerging Markets & Europe Formulations business
Emerging Markets & Europe Formulations business zyd~ Dedicated To Life Base business continued to display robust growth Highlights for the quarter EM & EU Formulations Sales (Rs. mn) Q1 FY24 Revenue Contribution ▪ The business continued its growth journey and 4,893 4,393 posted a robust 30% growth Y
Slide 11: Updates on Innovation
Updates on Innovation zyd~ Dedicated To Life NCE: Saroglitazar Magnesium • The molecule is undergoing Phase II(b)/III clinical trials for PBC indication and Phase II(b) clinical trials for NASH indication for the US market. Recruited over 80% of the patients for PBC trials. Patient recruitment is go
Slide 12: Zydus at a Glance
Zydus at a Glance zyd~ Dedicated To Life ~$2.15 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Among 1st Revenues from India Approved product for >40% In 65% of product Geography (Formulations Top 3 f
Slide 13: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) zyd~ Dedicated To Life Q1 'II Q1 YoY Q4 . . QoQ Rs. mn I I • . FY24 'I FY23 I gr. FY23 . . gr. Total Income from Ops. 51,396 39,644 29.6% 50,106 2.6% Gross Contribution (GC) 34,652 24,551 41.1% 33,146 4.5% Gross Margin % 67.4% 61.9% 66.2% Employee benefi
Slide 14: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations zyd~ Dedicated To Life I Q1 'I :' Q1 . YoY . Rs. mn I : FY24 I FY23 : gr. % A. On operating transactions (above EBITDA line) 274 -1,169 123.5% a. Included in COGS 3 -86 104% b. Part of other operating expenses (shown separately) 271 -1,083 B. On other income - -
Slide 15: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C